Articles tagged with: VCD

News»

[ by | Dec 6, 2011 12:22 pm | 4 Comments ]
Initial Treatment With Cyclophosphamide, Velcade, And Dexamethasone Compares Favorably In Terms Of Response Rates And Side Effects

Results of a recent study show that newly diagnosed multiple myeloma patients initially treated with a combination of cyclophosphamide, Velcade, and dexamethasone have better response rates and less severe side effects than patients treated with Revlimid-dexamethasone or cyclophosphamide-Revlimid-dexamethasone.

The survival outcomes for the patients treated with cyclophosphamide, Velcade, and dexamethasone also are promising.

However, the difference in survival rates between the three treatment regimens is not statistically significant.

This is partly because "the numbers [of patients in the study] were too small to show differences in survival,” explained Dr. Craig Reeder of the …

Read the full story »

News»

[ by | Jun 28, 2010 2:45 pm | Comments Off ]
Cyclophosphamide, Velcade, And Dexamethasone Combination Shows Promise For Newly Diagnosed Multiple Myeloma (ASCO 2010)

Treatment of newly diagnosed multiple myeloma patients with a combination of cyclophosphamide (Cytoxan), Velcade (bortezomib), and dexamethasone (Decadron) (abbreviated CyBorD) appears to be effective and safe. The findings were presented June 5 in a poster session at the American Society of Clinical Oncology (ASCO) annual meeting.

The study compared CyBorD with Revlimid (lenalidomide)-dexamethasone treatment (abbreviated RD) and cyclophosphamide-Revlimid-dexamethasone treatment (abbreviated CRD). The results of the Phase 2 trials indicate that RD and CyBorD treatment were similar in efficacy and safety. CRD, however, was not as effective and had …

Read the full story »